Antibiotics for myocardial infarction? A possible role of infection in atherogenesis and acute coronary syndromes

Drugs

Volumn 57, Issue 3, 1999, Pages 283-291

  Schussheim, Adam E ^a   Fuster, Valentin ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CYTOKINE; DOXYCYCLINE; MACROLIDE; ROXITHROMYCIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CORONARY ARTERY; CYTOMEGALOVIRUS; HEART INFARCTION; HELICOBACTER PYLORI; HERPES VIRUS; HUMAN; HYPERCOAGULABILITY; INFECTION; MACROPHAGE; MONOCYTE; NONHUMAN; REVIEW; SEROEPIDEMIOLOGY; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERIOSCLEROSIS; HUMANS; INFECTION; MYOCARDIAL INFARCTION;

EID: 0032983669     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957030-00002     Document Type: Review

References (52)

1. Ophuls W. Arteriosclerosis and cardiovascular disease. JAMA 1921; 76: 700-1.
2. Thom DH, Grayston JT, Siscovick DS, et al. Association of prior infection with Chlamydia pneumonia and angiographically demonstrated coronary artery disease. JAMA 1992; 268: 69-72.
3. Fabricant CG, Fabricant J, Litrenta MM, et al. Virus-induced atherosclerosis. J Exp Med 1978; 148: 335-40.
4. Libby P, Egan D, Skarlatos S. Role of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997; 96: 4095-103.
5. Cook PJ, Lip GYH. Infectious agents and atherosclerotic vascular disease. Q J Med 1996; 89: 727-35.
6. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology [published erratum appears in Circulation 1995 Jan 1; 91 (1): 256]. Circulation 1994; 90: 2126-46.
7. Fuster V. Human lesion studies. In: Numano F, Ross R, editors. Atherosclerosis IV: recent advances in atherosclerosis research. New York City: The New York Academy of Sciences, 1997: 207-25.
8. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis 1997; 39: 287-324.
9. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50.
10. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 310-8.
11. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1989; 99: I-19-32.
12. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
13. Ambrose JA, Tannenbaum M, Alexpoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12: 56-62.
14. Libby P. Atheroma: more than mush. Lancet 1996; 348: s4-7.
15. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atheroselerotic plaques. Lancet 1989; 11: 1462-3.
16. Fuster V, Fallon JT, Nemerson Y. Coronary thrombosis. Lancet 1996; 348: s7-10.
17. Wang P, Ba ZE, Chaudry IH. Administration of tumor necrosis factor-α in vivo depresses endothelium-dependent relaxation. Am J Physiol 1994; 266: H2535-41.
18. Bhagat K, Moss R, Collier J, et al. Endothelial 'stunning' following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res 1996; 32: 822-9.
19. Hajjar DP, Pomerantz KB, Falcone DJ, et al. Herpes simplex virus infection in human arterial cells: implications in arteriosclerosis. J Clin Invest 1987; 80: 1317-21.
20. Epstein SE, Speir E, Zhou YF, et al. The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus. Lancet 1996; 348: s13-7.
21. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
22. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 1997; 349: 1391-2.
23. Woordhouse PR, Khaw KT, Plummer M, et al. Seasonal variation of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet 1994; 343: 435-9.
24. Sammalkorpi K, Valtonen V, Kerttula Y, et al. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 1988; 37: 859-65.
25. Melnick JL, Adam E, DeBakey ME. Possible role of cytomegalovirus in atherogenesis. JAMA 1990; 263: 2204-7.
26. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561-6.
27. Lemstrom K, Sihvola R, Bruggeman C, et al. Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. Circulation 1997; 95: 2614-6.
28. Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996; 335: 624-30.
29. Guetta E, Guetta V, Shibutani T, et al. Monocytes harboring cytomegalovirus: interactions with endothelial cells, smooth muscle cells, and oxidized low-density lipoprotein. Circ Res 1997; 81: 8-16.
30. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science 1997; 276: 1857-61.
31. Speir E, Modali R, Huang ES, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994; 265: 391-4.
32. Mendall MA, Goggin PM, Molineaux N, et al. Relation of Helicobacter pylori and coronary heart disease. Br Heart J 1994; 71: 437-9.
33. Patel P, Mendall MA, Carrington D, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995; 311: 711-4.
34. Wald NJ, Law MR, Morris JK, et al. Helicobacter pylori infection and mortality from ischaemic heart disease; negative result from a large, prospective study. BMJ 1997; 315: 1199-201.
35. Niemela S, Karttunen T, Korhonen T, et al. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart 1996; 75: 573-5.
36. Whincup PH, Mendall MA, Perry IJ, et al. Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle aged men. Heart 1996; 75: 568-72.
37. Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ 1998; 316: 1130-2.
38. Cook PJ, Honeybourne D. Chlamydia pneumoniae. J Antimicrob Chemother 1994; 34: 859-73.
39. Campbell LA, O'Brien ER, Cappuccio AL, et al. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis 1995; 172: 585-8.
40. Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996; 27: 1555-61.
41. Ramirez JA. Chlamydia pneumoniae/Atherosclerosis study group. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med 1996; 125: 979-82.
42. Fong IW, Chiu B, Viira E, et al. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997; 35: 48-52.
43. Laitinen K, Laurila A, Pyhala L, et al. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 1997; 65: 4832-5.
44. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-6.
45. Saikku P, Leinnnen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary artery disease and myocardial infarction. Lancet 1988; 2: 983-6.
46. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116: 273-8.
47. Thom DH, Wang SP, Grayston JT, et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterionscler Thromb 1991; 11: 547-51.
48. Miettinen H, Lehto S, Saikku P, et al. Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland. Eur Heart J 1996; 17: 682-8.
49. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7.
50. Gurfinkel E, Bozovich G, Daroca A, et al. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997; 350: 404-7.
51. Gurfinkel E, Bozovich G, Mejail I, et al. Roxithromycin in the Non-Q-Wave Coronary Events: final results of the ROXIS study at 6 months follow-up [abstract]. J Am Coll Cardiol 1998; 31: 451A.
52. Petrinec D, Liao S, Holmer DR, et al. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92kD gelatinase. J Vase Surg 1996; 23: 336-46.